GAM Holding AG Buys 540 Shares of Eli Lilly and Company $LLY

GAM Holding AG increased its position in Eli Lilly and Company (NYSE:LLY) by 2.7% during the third quarter, Holdings Channel.com reports. The firm owned 20,523 shares of the company’s stock after buying an additional 540 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of GAM Holding AG’s holdings, making the stock its 19th biggest position. GAM Holding AG’s holdings in Eli Lilly and Company were worth $15,659,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company during the second quarter worth $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. boosted its stake in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $31,000. Finally, Bare Financial Services Inc increased its position in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,079.83 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.83, a PEG ratio of 0.78 and a beta of 0.35. The stock’s fifty day moving average price is $1,013.16 and its 200 day moving average price is $850.82.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the company earned $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks upgraded LLY from Hold to Strong Buy, a near-term catalyst that can attract buying from model-driven and income-focused investors. Zacks Research upgrade
• Positive Sentiment: Articles pushing a potential “surprise dividend” narrative have resurfaced, boosting investor interest in Lilly as a must-own 2026 idea if management signals shareholder returns. Eli Lilly’s surprise dividend story could be a 2026 must-own
• Positive Sentiment: Investor write-ups (e.g., InsiderMonkey) reiterate Lilly’s strong fundamentals and leadership in GLP-1s, supporting the case for LLY as a core holding. Positive third‑party commentary can sustain buying. What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
• Positive Sentiment: MarketBeat flagged Lilly’s progress advancing two additional weight‑loss drugs (one nearing approval) — successful trial/approval news would be a major upside catalyst for revenue growth. Eli Lilly’s new drug data sets up a high‑stakes 2026
• Neutral Sentiment: Broader market strength at the start of 2026 lifted many large caps, including LLY; macro momentum (vs. company-specific news) is supporting the move. MarketBeat Week in Review – 12/29 – 01/02
• Neutral Sentiment: Coverage noting price cuts for GLP‑1 drugs in China (Novo and reports of LLY pricing moves) highlights regional pricing pressure — this could temper upside but impact is currently uncertain and depends on scale. Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
• Negative Sentiment: Two recent commercials have drawn viewer backlash and accusations over messaging; while not yet a material business issue, negative publicity can affect brand perception and invite scrutiny. Company Facing Backlash For ‘Ridiculous’ Rose Bowl Commercial
• Negative Sentiment: Another piece highlights viewer division over an alleged “pro‑obesity” message in a new ad — reputational noise that could weigh on sentiment if amplified. New Eli Lilly commercial divides viewers

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Berenberg Bank upped their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research report on Tuesday, December 2nd. UBS Group restated a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.